A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, Oct. 25, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to...
NEW YORK, Sept. 02, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences: H.C. Wainwright 23rd Annual...
NEW YORK, Aug. 10, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June...
NEW YORK, Aug. 09, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities...
NEW YORK, Aug. 05, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in two upcoming conferences: BTIG Virtual...
NEW YORK, July 28, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time...
NEW YORK, July 07, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The...
NEW YORK, June 08, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell...
As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for...
NEW YORK, June 03, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at: LD Micro Virtual Investor ConferenceDate:...